BAVIS_1170X120_10-19-20

Marc Kikuchi

Dr. Reddy’s rolls out generic version of Ciprodex

Dr. Reddy’s rolls out generic version of Ciprodex

PRINCETON, N.J. – Dr. Reddy’s  announced the launch of ciprofloxacin 0.3% and dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

PRINCETON, N.J. — Dr. Reddy’s announced the launch of desmopressin acetate injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9

Dr. Reddy’s rolls out pre-filled naloxone syringes

Dr. Reddy’s rolls out pre-filled naloxone syringes

PRINCETON,  N.J.— Dr. Reddy’s Laboratories announced Monday the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring our second product to market that has been

Dr. Reddy’s introduces ziprasidone mesylate for injection

Dr. Reddy’s introduces ziprasidone mesylate for injection

PRINCETON, N.J. — Dr. Reddy’s  has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration. “We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from

Dr. Reddy’s launches trientine hydrochloride capsules

Dr. Reddy’s launches trientine hydrochloride capsules

PRINCETON, N.J. — Dr. Reddy’s announced the launch of trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration. “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

PRINCETON, N.J.— Dr. Reddy’s Laboratories announced this week the re-launch of its buprenorphine and naloxone sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The re-launch comes on the heels of a favorable